Home
Scholarly Works
Medication rules of ancient Tazi prescriptions for...
Journal article

Medication rules of ancient Tazi prescriptions for Chuangyang and prospects for new drug development based on big data analysis

Abstract

Objective: Based on the analysis using big data, the medication rules of Tazi prescriptions for Chuangyang were summarizedto provide inheritance basis for the development of modern Chinese medicines for external use, and to explore the development of new Chinese medicines for external use. Methods: The ancient Tazi prescriptions of Chuangyang was screened in Traditional Chinese Medicine Classic Database since the Spring and Autumn Period and the Warring States Period. The data mining technology, such as frequency and correlation analysis were used to analyze the characteristics and regularity of high frequency single-drug, drug groups, and new prescriptions from the view of clinical application combined with the existing commercially available external proprietary Chinese medicines for Chuangyang. Results: A total of 423 ancient prescriptions were collected, involving 280 traditional Chinese medicines. Spicy, bitter and sweet taste were the main medicinal properties. The high frequency single-drugs meridians enter the spleen, liver and kidney meridians, and their main effects were relieving pain, detoxification, clearing heat, and eliminating dampness. In the results of correlation analysis, high-frequency drug groups include Scutellaria baicalensis-Coptis chinensis, Angelica-Licorice, and Scutellaria baicalensis-Licorice. There are 6 new prescriptions, including Scutellaria-Phellodendron-Sophora-Sophora-Honeysuckle-Dandelion-White Peony-Centipede-Forsythia, Angelica-Asarum-Nepeta-Honeysuckle-Dew Hive-Angelica and so on. Conclusion: The ancient prescriptions for the treatment of Chuangyang are mainly used to relieving pain and detoxification, clearing heat and drying dampness, promoting blood circulation, as well as removing rot and pus. Combined with the current marketed external medicines for the treatment of Chuangyang, new drugs still need further research and development.

Authors

Wang N; Ju S; Li C; Yang GY; Deng LJ; Zhang Y; Zhou T; Wang XW; Wang G; Li YB

Journal

Chinese Journal of New Drugs, Vol. 30, No. 17, pp. 1565–1569

Publication Date

September 15, 2021

ISSN

1003-3734

Contact the Experts team